Fate Therapeutics (NASDAQ:FATE) and TCR2 Therapeutics (NASDAQ:TCRR) Head to Head Comparison
Fate Therapeutics (NASDAQ:FATE) and TCR2 Therapeutics (NASDAQ:TCRR) Head to Head Comparison
Fate Therapeutics (NASDAQ:FATE – Get Rating) and TCR2 Therapeutics (NASDAQ:TCRR – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, risk and valuation.
Fate Therapeutics（纳斯达克股票代码：FATE — 获取评级）和TCR2 Therapeutics（纳斯达克股票代码：TCRR — 获取评级）都是小盘股医疗公司，但哪家是最佳投资？我们将根据两家企业的机构所有权实力、分析师建议、股息、盈利能力、收益、风险和估值来比较这两家企业。
Profitability
盈利能力
This table compares Fate Therapeutics and TCR2 Therapeutics' net margins, return on equity and return on assets.
该表比较了Fate Therapeutics和TCR2 Therapeutics的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Fate Therapeutics | -292.55% | -50.86% | -36.11% |
| TCR2 Therapeutics | N/A | -73.97% | -54.59% |
| 净利润 | 股本回报率 | 资产回报率 | |
| 命运疗法 | -292.55% | -50.86% | -36.11% |
| TCR2 疗法 | 不适用 | -73.97% | -54.59% |
Risk & Volatility
风险与波动性
Fate Therapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500. Comparatively, TCR2 Therapeutics has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500.
Fate Therapeutics的beta值为1.49，这意味着其股价的波动性比标准普尔500指数高49％。相比之下，TCR2 Therapeutics的beta值为1.93，这意味着其股价的波动性比标准普尔500指数高93％。
Analyst Recommendations
分析师建议
This is a breakdown of current ratings and recommmendations for Fate Therapeutics and TCR2 Therapeutics, as provided by MarketBeat.com.
这是Marketbeat.com提供的Fate Therapeutics和TCR2 Therapeutics当前的评级和推荐明细。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fate Therapeutics | 2 | 15 | 5 | 0 | 2.14 |
| TCR2 Therapeutics | 0 | 6 | 2 | 0 | 2.25 |
| 卖出评级 | 保持收视率 | 买入评级 | 强劲的买入评级 | 评分分数 | |
| 命运疗法 | 2 | 15 | 5 | 0 | 2.14 |
| TCR2 疗法 | 0 | 6 | 2 | 0 | 2.25 |
Fate Therapeutics presently has a consensus price target of $19.44, suggesting a potential upside of 233.98%. TCR2 Therapeutics has a consensus price target of $4.91, suggesting a potential upside of 171.51%. Given Fate Therapeutics' higher possible upside, equities research analysts plainly believe Fate Therapeutics is more favorable than TCR2 Therapeutics.
Fate Therapeutics目前的共识目标股价为19.44美元，表明潜在的上涨空间为233.98％。TCR2 Therapeutics的共识目标股价为4.91美元，表明潜在的上涨空间为171.51％。鉴于Fate Therapeutics可能有更高的上行空间，股票研究分析师显然认为Fate Therapeutics比TCR2 Therapeutics更有利。
Earnings and Valuation
收益和估值
This table compares Fate Therapeutics and TCR2 Therapeutics' gross revenue, earnings per share and valuation.
该表比较了Fate Therapeutics和TCR2 Therapeutics的总收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Fate Therapeutics | $96.30 million | 5.94 | -$281.72 million | ($2.91) | -2.00 |
| TCR2 Therapeutics | N/A | N/A | -$151.82 million | ($3.93) | -0.46 |
| 总收入 | 价格/销售比率 | 净收入 | 每股收益 | 市盈率 | |
| 命运疗法 | 9,630 万美元 | 5.94 | -2.8172 亿美元 | (2.91 美元) | -2.00 |
| TCR2 疗法 | 不适用 | 不适用 | -1.5182 亿美元 | （3.93 美元） | -0.46 |
TCR2 Therapeutics has lower revenue, but higher earnings than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than TCR2 Therapeutics, indicating that it is currently the more affordable of the two stocks.
TCR2 Therapeutics的收入较低，但收益高于Fate Therapeutics。Fate Therapeutics的交易市盈率低于TCR2 Therapeutics，这表明它目前是这两只股票中更实惠的一只。
Institutional & Insider Ownership
机构所有权和内部所有权
64.8% of TCR2 Therapeutics shares are held by institutional investors. 17.3% of Fate Therapeutics shares are held by insiders. Comparatively, 25.0% of TCR2 Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
64.8％的TCR2 Therapeutics股票由机构投资者持有。17.3％的Fate Therapeutics股票由内部人士持有。相比之下，25.0％的TCR2 Therapeutics股票由内部人士持有。强大的机构所有权表明大型基金经理、捐赠基金和对冲基金认为股票有望实现长期增长。
Summary
摘要
TCR2 Therapeutics beats Fate Therapeutics on 7 of the 13 factors compared between the two stocks.
TCR2 Therapeutics在两只股票比较的13个因素中有7个击败了Fate Therapeutics。
About Fate Therapeutics
关于 Fate Therape
(Get Rating)
（获取评分）
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
Fate Therapeutics, Inc. 参与开发针对癌症和免疫障碍的程序化细胞免疫疗法。其产品线包括免疫生态学候选药物和免疫调节候选药物。该公司由 Philip Beachy、Shing Ding、Rudolf Jaenisch、Randall T. Moon、Michael Rudnicki、David Scadden、Leonard Zon、Alexander Rives、Scott Wolchko 和 John D. Mendlein 于 2007 年 4 月 27 日创立，总部位于加利福尼亚州圣地亚哥。
About TCR2 Therapeutics
关于 TCR2 疗法
(Get Rating)
（获取评分）
TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.
TCR2 Therapeutics, Inc. 是一家临床阶段的细胞疗法公司，从事用于癌症治疗的生物药物的开发和设计 T 细胞。它还参与了与学术实验室和行业合作伙伴在T细胞免疫学、细胞疗法、基因编辑和工艺开发领域的研究与合作。该公司由 Patrick A. Baeuerle 于 2015 年 5 月 29 日创立，总部位于马萨诸塞州剑桥。
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Fate Therapeutics 每日新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Fate Therapeutics及相关公司的最新新闻和分析师评级的简明每日摘要。